Total Payments
$13,276
2024 Payments
$6,253
Companies
15
Transactions
85
Medicare Patients
2,024
Medicare Billing
$208,782
Payment Breakdown by Category
Food & Beverage$7,200 (54.2%)
Consulting$4,161 (31.3%)
Travel$1,862 (14.0%)
Education$52.94 (0.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,200 | 72 | 54.2% |
| Consulting Fee | $4,161 | 1 | 31.3% |
| Travel and Lodging | $1,862 | 6 | 14.0% |
| Education | $52.94 | 6 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $6,235 | 11 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $3,153 | 31 | $0 (2023) |
| Amarin Pharma Inc. | $938.28 | 13 | $0 (2019) |
| Amgen Inc. | $788.44 | 7 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $422.07 | 4 | $0 (2017) |
| AbbVie, Inc. | $403.18 | 4 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $367.77 | 4 | $0 (2018) |
| Kowa Pharmaceuticals America, Inc. | $249.98 | 2 | $0 (2018) |
| Daiichi Sankyo Inc. | $194.08 | 1 | $0 (2018) |
| Novo Nordisk Inc | $193.51 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,253 | 12 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($6,235) |
| 2023 | $349.91 | 4 | Amgen Inc. ($227.92) |
| 2022 | $252.88 | 3 | AstraZeneca Pharmaceuticals LP ($252.88) |
| 2021 | $115.35 | 1 | Bayer HealthCare Pharmaceuticals Inc. ($115.35) |
| 2019 | $1,148 | 13 | AstraZeneca Pharmaceuticals LP ($697.37) |
| 2018 | $1,795 | 17 | AstraZeneca Pharmaceuticals LP ($661.76) |
| 2017 | $3,362 | 35 | AstraZeneca Pharmaceuticals LP ($1,436) |
All Payment Transactions
85 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REJOYN (Device) | Travel and Lodging | Cash or cash equivalent | $34.17 | General |
| Category: PSYCHIATRY | ||||||
| 12/09/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REJOYN (Device) | Consulting Fee | Cash or cash equivalent | $4,161.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/09/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REJOYN (Device) | Travel and Lodging | Cash or cash equivalent | $79.76 | General |
| Category: PSYCHIATRY | ||||||
| 12/09/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REJOYN (Device) | Travel and Lodging | Cash or cash equivalent | $75.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/09/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REJOYN (Device) | Travel and Lodging | Cash or cash equivalent | $71.10 | General |
| Category: PSYCHIATRY | ||||||
| 11/12/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REJOYN (Device) | Food and Beverage | In-kind items and services | $78.14 | General |
| Category: PSYCHIATRY | ||||||
| 11/12/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REJOYN (Device) | Food and Beverage | In-kind items and services | $44.65 | General |
| Category: PSYCHIATRY | ||||||
| 11/12/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REJOYN (Device) | Food and Beverage | In-kind items and services | $19.09 | General |
| Category: PSYCHIATRY | ||||||
| 11/11/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REJOYN (Device) | Travel and Lodging | In-kind items and services | $1,320.96 | General |
| Category: PSYCHIATRY | ||||||
| 11/11/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REJOYN (Device) | Travel and Lodging | In-kind items and services | $281.10 | General |
| Category: PSYCHIATRY | ||||||
| 11/11/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REJOYN (Device) | Food and Beverage | In-kind items and services | $69.61 | General |
| Category: PSYCHIATRY | ||||||
| 04/11/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: Oncology | ||||||
| 11/02/2023 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $106.75 | General |
| Category: Cardiology | ||||||
| 09/13/2023 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $121.17 | General |
| Category: Cardiology | ||||||
| 08/09/2023 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $16.62 | General |
| Category: Oncology | ||||||
| 06/13/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $105.37 | General |
| Category: Respiratory | ||||||
| 11/17/2022 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $72.33 | General |
| Category: Respiratory | ||||||
| 05/24/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $111.92 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/07/2022 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $68.63 | General |
| Category: Respiratory | ||||||
| 10/22/2021 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $115.35 | General |
| Category: Cardio-renal | ||||||
| 11/07/2019 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $124.55 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/24/2019 | SANOFI PASTEUR INC. | FLUZONE HIGH-DOSE (Drug), FLUBLOK QUADRIVALENT, FLUZONE QUADRIVALENT | Food and Beverage | In-kind items and services | $11.17 | General |
| Category: VACCINES | ||||||
| 08/28/2019 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $95.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/08/2019 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $123.31 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/11/2019 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $95.94 | General |
| Category: Hypertriglyceridemia | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 566 | 740 | $175,552 | $63,247 |
| 2022 | 12 | 555 | 684 | $151,348 | $61,368 |
| 2021 | 10 | 462 | 538 | $107,748 | $49,294 |
| 2020 | 9 | 441 | 505 | $87,810 | $34,873 |
Total Patients
2,024
Total Services
2,467
Medicare Billing
$208,782
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 190 | 355 | $90,880 | $24,684 | 27.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 165 | 165 | $43,230 | $20,543 | 47.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 30 | 35 | $12,635 | $4,273 | 33.8% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 12 | 12 | $6,360 | $3,361 | 52.8% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 41 | 42 | $6,186 | $3,140 | 50.8% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 13 | 13 | $4,355 | $2,086 | 47.9% |
| 91320 | Sarscv2 vac 30mcg trs-suc im | Office | 2023 | 15 | 15 | $4,320 | $1,927 | 44.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 43 | 45 | $2,160 | $1,347 | 62.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 13 | $2,366 | $677.36 | 28.6% |
| 90480 | Admn sarscov2 vacc 1 dose | Office | 2023 | 15 | 15 | $1,350 | $598.80 | 44.4% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 12 | 12 | $576.00 | $359.28 | 62.4% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 17 | 18 | $1,134 | $250.88 | 22.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 185 | 313 | $73,555 | $21,442 | 29.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 138 | 138 | $31,740 | $17,780 | 56.0% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2022 | 27 | 27 | $14,310 | $7,519 | 52.5% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2022 | 22 | 22 | $7,480 | $3,488 | 46.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 25 | 25 | $7,875 | $2,903 | 36.9% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2022 | 17 | 17 | $5,627 | $2,806 | 49.9% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 36 | 36 | $4,392 | $2,529 | 57.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 39 | 39 | $1,872 | $1,131 | 60.4% |
| G0009 | Administration of pneumococcal vaccine | Office | 2022 | 29 | 29 | $1,392 | $843.64 | 60.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 11 | 11 | $1,760 | $642.34 | 36.5% |
| 71046 | X-ray of chest, 2 views | Office | 2022 | 12 | 13 | $598.00 | $182.50 | 30.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 14 | 14 | $747.00 | $101.65 | 13.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 137 | 137 | $27,811 | $18,036 | 64.9% |
About Dr. Gregorius Penilla, M.D
Dr. Gregorius Penilla, M.D is a Internal Medicine healthcare provider based in Fenton, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023024973.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregorius Penilla, M.D has received a total of $13,276 in payments from pharmaceutical and medical device companies, with $6,253 received in 2024. These payments were reported across 85 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($7,200).
As a Medicare-enrolled provider, Penilla has provided services to 2,024 Medicare beneficiaries, totaling 2,467 services with total Medicare billing of $208,782. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Fenton, MO
- Active Since 07/31/2006
- Last Updated 10/26/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1023024973
Products in Payments
- REJOYN (Device) $6,235
- FARXIGA (Drug) $1,804
- Vascepa (Drug) $938.28
- BYDUREON (Drug) $851.91
- Repatha (Biological) $668.14
- JARDIANCE (Drug) $422.07
- BELSOMRA (Drug) $296.23
- Livalo (Drug) $249.98
- BREZTRI (Drug) $246.33
- Synthroid (Drug) $204.42
- Androgel (Drug) $198.76
- Morphabond ER (Drug) $194.08
- Victoza (Drug) $193.51
- MOVANTIK (Drug) $125.50
- BEVESPI AEROSPHERE (Drug) $125.00
- Aimovig (Biological) $120.30
- Kerendia (Drug) $115.35
- XIFAXAN (Drug) $95.27
- PRALUENT (Drug) $74.92
- STEGLATRO (Drug) $71.54
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Fenton
Soon Choi, Md, MD
Internal Medicine — Payments: $12,647
Internal Medicine $12,647
Dr. Aman Patel, Do, DO
Internal Medicine — Payments: $11,738
Internal Medicine $11,738
Niketa Dani, Md, MD
Internal Medicine — Payments: $6,819
Internal Medicine $6,819
Dr. Mohan Palla, M.d, M.D
Internal Medicine — Payments: $3,943
Internal Medicine $3,943
Sri Kolli, M.d, M.D
Internal Medicine — Payments: $3,463
Internal Medicine $3,463
Edward Reh, M.d, M.D
Internal Medicine — Payments: $2,467
Internal Medicine $2,467